1. Home
  2. TAK
  3. TAK News

Latest Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) (TAK) News on March 20, 2025

TAK or DSNKY: Which Is the Better Value Stock Right Now?
TAK

Zacks

6 days ago

TAK or DSNKY: Which Is the Better Value Stock Right Now?

Takeda’s $770M deal deepens Big Pharma’s omics push
TAK

Pharma Voice

7 days ago

Takeda’s $770M deal deepens Big Pharma’s omics push

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
TAK

Benzinga

16 days ago

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Takeda and Protagonist report topline outcomes from trial of rusfertide
TAK

Clinical Trials Arena

17 days ago

Takeda and Protagonist report topline outcomes from trial of rusfertide

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
TAK

Zacks

17 days ago

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

TAK

MT Newswires

17 days ago

Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
TAK

Business Wire

17 days ago

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Protagonist says Takeda-partnered drug succeeds in rare blood cancer
TAK

BioPharma Dive

17 days ago

Protagonist says Takeda-partnered drug succeeds in rare blood cancer

Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now?
TAK

Insider Monkey

21 days ago

Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now?

Takeda broadens its deal with BridGene for up to $770m
TAK

Pharmaceutical Technology

22 days ago

Takeda broadens its deal with BridGene for up to $770m

EMA approves Takeda’s Takhzyro pre-filled pen option for HAE
TAK

Pharmaceutical Technology

23 days ago

EMA approves Takeda’s Takhzyro pre-filled pen option for HAE

TAK

MT Newswires

24 days ago

Takeda Secures EMA Approval for Additional Injection Option for Hereditary Angioedema Drug

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
TAK

PR Newswire

24 days ago

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

TAK vs. DSNKY: Which Stock Is the Better Value Option?
TAK

Zacks

a month ago

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?
TAK

Insider Monkey

a month ago

Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
TAK

Zacks

a month ago

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

BBI announces $31m facility for Shire to enhance asset finance
TAK

Leasing Life

a month ago

BBI announces $31m facility for Shire to enhance asset finance

Are orexins the next golden child of neuroscience?
TAK

Pharma Voice

a month ago

Are orexins the next golden child of neuroscience?

Takeda announces appointment of Julie Kim as CEO
TAK

Pharmaceutical Technology

2 months ago

Takeda announces appointment of Julie Kim as CEO

Christophe Weber, veteran Takeda CEO, to retire next year
TAK

BioPharma Dive

2 months ago

Christophe Weber, veteran Takeda CEO, to retire next year

TAK

MT Newswires

2 months ago

Takeda Pharmaceutical Names Julie Kim Chief Executive

TAK

MT Newswires

2 months ago

Takeda Pharmaceutical Fiscal Q3 Core Earnings Decline, Revenue Rises

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
TAK

Business Wire

2 months ago

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
TAK

Business Wire

2 months ago

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

TAK

MT Newswires

2 months ago

Takeda Pharmaceutical Says Hema-Quebec to Cover HyQvia for Immunodeficiency Treatment

Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age
TAK

CNW Group

2 months ago

Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
TAK

Benzinga

2 months ago

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights

TAK

MT Newswires

2 months ago

Neurocrine Amends Collaboration with Takeda on Osavampator

TAK

MT Newswires

2 months ago

Keros to Receive $200 Million From Takeda In Connection to Elritercept License Deal

Takeda Recognized as a Top Employer in Canada for Third Consecutive Year
TAK

CNW Group

2 months ago

Takeda Recognized as a Top Employer in Canada for Third Consecutive Year

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept
TAK

GlobeNewswire

2 months ago

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

Health Canada gives Takeda’s mCRC capsules market authorisation
TAK

Pharmaceutical Technology

2 months ago

Health Canada gives Takeda’s mCRC capsules market authorisation

TAK

MT Newswires

2 months ago

Takeda Canada Says Health Canada Granted Market Authorization for Fruzaqla

Takeda's FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC)
TAK

CNW Group

2 months ago

Takeda's FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC)

Japanese Stocks Are in the Spotlight Again. Hopes Are High for 2025.
TAK

Barrons.com

3 months ago

Japanese Stocks Are in the Spotlight Again. Hopes Are High for 2025.

TAK

MT Newswires

3 months ago

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency
TAK

Benzinga

3 months ago

Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency

TAK

MT Newswires

3 months ago

Takeda Pharmaceutical's Hyqvia Approved in Japan for Patients With Immune Disorders

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
TAK

Business Wire

3 months ago

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative
TAK

CNW Group

3 months ago

Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative

Takeda Announces Subsidiary Liquidation and Merger Completion
TAK

TipRanks

3 months ago

Takeda Announces Subsidiary Liquidation and Merger Completion

TAK

MT Newswires

3 months ago

Hutchmed to Receive $10 Million Milestone Payment Through Takeda

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
TAK

GlobeNewswire

3 months ago

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
TAK

Business Wire

3 months ago

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Novavax sells Czech plant to Novo; Relay licenses out a cancer drug
TAK

BioPharma Dive

4 months ago

Novavax sells Czech plant to Novo; Relay licenses out a cancer drug

Takeda licensed for anaemia therapy by Keros Therapeutics
TAK

Pharmaceutical Technology

4 months ago

Takeda licensed for anaemia therapy by Keros Therapeutics

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
TAK

Benzinga

4 months ago

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst

TAK

MT Newswires

4 months ago

Keros Therapeutics Enters Global Development, License Deal with Takeda Pharmaceutical for Elritercept

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept
TAK

GlobeNewswire

4 months ago

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
TAK

Business Wire

4 months ago

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

Takeda’s Strong FY2024 H1 Boosts Full-Year Outlook
TAK

TipRanks

4 months ago

Takeda’s Strong FY2024 H1 Boosts Full-Year Outlook

Why Takeda (TAK) Is One of the Most Profitable Pharmaceutical Stocks Right Now?
TAK

Insider Monkey

4 months ago

Why Takeda (TAK) Is One of the Most Profitable Pharmaceutical Stocks Right Now?

Takeda Canada co-sponsors grant to boost IBD clinical research
TAK

Clinical Trials Arena

4 months ago

Takeda Canada co-sponsors grant to boost IBD clinical research

TAK

MT Newswires

4 months ago

Hutchmed to Receive Milestone Payment for Takeda's Fruzaqla Launch in Japan

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
TAK

GlobeNewswire

4 months ago

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies
TAK

Pharmaceutical Technology

4 months ago

Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies

Why this major drugmaker no longer has an ‘IT department’
TAK

Fortune

4 months ago

Why this major drugmaker no longer has an ‘IT department’

New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD
TAK

CNW Group

5 months ago

New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD

TAK

MT Newswires

5 months ago

HUTCHMED Earns $20 Million Milestone Payment After Takeda Reaches Over $200 Million in Fruquintinib Sales

TAK

MT Newswires

5 months ago

Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Increase; Fiscal-Year Outlook Raised

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
TAK

GlobeNewswire

5 months ago

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
TAK

Business Wire

5 months ago

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q2 2025 Earnings
TAK

GuruFocus.com

5 months ago

What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q2 2025 Earnings

Takeda and BMC partner to decarbonise US healthcare sector
TAK

Pharmaceutical Technology

5 months ago

Takeda and BMC partner to decarbonise US healthcare sector

TAK

MT Newswires

5 months ago

Takeda Pharmaceutical, Boston Medical Center Team Up for Decarbonization Project

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
TAK

Business Wire

5 months ago

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

TAK

Leasing Life

5 months ago

Deko and Shire Leasing partner to offer B2B leasing at checkout

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
TAK

Benzinga

5 months ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Strategic Moves in the Japanese Market: T. Rowe Price Japan Fund's Focus on Takeda Pharmaceutical
TAK

GuruFocus.com

5 months ago

Strategic Moves in the Japanese Market: T. Rowe Price Japan Fund's Focus on Takeda Pharmaceutical

WAVE Life Sciences Ltd (WVE) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...
TAK

GuruFocus.com

5 months ago

WAVE Life Sciences Ltd (WVE) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...

TAK

MT Newswires

5 months ago

Takeda Forms Joint Venture With Astellas, Sumitomo Mitsui to Develop Early-Drug Discovery Programs in Japan

TAK or CTLT: Which Is the Better Value Stock Right Now?
TAK

Zacks

6 months ago

TAK or CTLT: Which Is the Better Value Stock Right Now?

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
TAK

Zacks

6 months ago

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?

Tempus Stock Up Following Collaboration Expansion in Oncology R&D
TAK

Zacks

6 months ago

Tempus Stock Up Following Collaboration Expansion in Oncology R&D

How Many Stocks Should You Own?
TAK

Zacks

6 months ago

How Many Stocks Should You Own?

Tempus AI expands oncology collaboration with Takeda
TAK

Pharmaceutical Technology

6 months ago

Tempus AI expands oncology collaboration with Takeda

TAK

MT Newswires

6 months ago

Tempus AI Expands Takeda Partnership to Support Cancer Drug Research

TAK

MT Newswires

6 months ago

Alvotech Starts Confirmatory Study for Biosimilar Candidate to Entyvio

The Zacks Analyst Blog Highlights Takeda Pharma, Naspers and Packaging Corp. of America
TAK

Zacks

6 months ago

The Zacks Analyst Blog Highlights Takeda Pharma, Naspers and Packaging Corp. of America

Takeda’s FRUZAQLA approved in Japan for advanced colorectal cancer
TAK

Pharmaceutical Technology

6 months ago

Takeda’s FRUZAQLA approved in Japan for advanced colorectal cancer

TAK

MT Newswires

6 months ago

Takeda Pharmaceutical Says Colorectal Cancer Drug Received Marketing Approval in Japan

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
TAK

Business Wire

6 months ago

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
TAK

GlobeNewswire

6 months ago

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

MHRA approves Takeda’s fruquintinib for metastatic colorectal cancer
TAK

Pharmaceutical Technology

6 months ago

MHRA approves Takeda’s fruquintinib for metastatic colorectal cancer

Takeda Pharmaceutical Company Limited (TAK): Hedge Funds Are Bullish On This Japanese Stock Now
TAK

Insider Monkey

6 months ago

Takeda Pharmaceutical Company Limited (TAK): Hedge Funds Are Bullish On This Japanese Stock Now

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
TAK

Business Wire

6 months ago

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

Lupin and Takeda to commercialise Vonoprazan in India
TAK

Pharmaceutical Technology

6 months ago

Lupin and Takeda to commercialise Vonoprazan in India

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
TAK

Business Wire

6 months ago

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

TAK vs. STVN: Which Stock Is the Better Value Option?
TAK

Zacks

6 months ago

TAK vs. STVN: Which Stock Is the Better Value Option?

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
TAK

Zacks

6 months ago

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

Vatroslav Mateljic Appointed General Manager of Takeda Canada
TAK

CNW Group

6 months ago

Vatroslav Mateljic Appointed General Manager of Takeda Canada

Buyout Firm GTCR Is in Advanced Talks to Acquire German Drugmaker Stada
TAK

Bloomberg

6 months ago

Buyout Firm GTCR Is in Advanced Talks to Acquire German Drugmaker Stada

Investors are waking up to Centessa’s sleepiness drug
TAK

BioPharma Dive

6 months ago

Investors are waking up to Centessa’s sleepiness drug

Takeda Pharmaceutical Company Limited (TAK): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
TAK

Insider Monkey

7 months ago

Takeda Pharmaceutical Company Limited (TAK): A Cheap Pharmaceutical Stock to Buy According to Short Sellers

Takeda’s ADZYNMA gains EU approval for cTTP treatment
TAK

Pharmaceutical Technology

7 months ago

Takeda’s ADZYNMA gains EU approval for cTTP treatment

Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
TAK

Benzinga

7 months ago

Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?

TAK

MT Newswires

7 months ago

Takeda Wins European Commission's Approval for Adzynma to Treat Blood Clotting Disorder

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
TAK

Business Wire

7 months ago

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Japan Fund That Beat 92% of Peers in 2024 Touts Seven & I, Orix
TAK

Bloomberg

7 months ago

Japan Fund That Beat 92% of Peers in 2024 Touts Seven & I, Orix

Japan’s Selloff Sank Global Markets. Why This Fund Manager Is Still Bullish.
TAK

Barrons.com

7 months ago

Japan’s Selloff Sank Global Markets. Why This Fund Manager Is Still Bullish.

Share on Social Networks: